University of Pittsburgh
Welcome,         Profile    Billing    Logout  
 1089 Trials 
2761 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reynolds, Charles
NCT00898755: Collecting and Storing Tissue From Young Patients With Cancer

Active, not recruiting
N/A
213
Canada, US
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma
12/25
12/25
Reis, Steven
HeartSCORE, NCT00143923: Novel Strategies for Reducing Heart Disease Risk Disparities

Active, not recruiting
N/A
2000
US
Nutrition, Exercise, Stress Management Counseling, usual care
University of Pittsburgh, Pennsylvania Department of Health
Cardiovascular Diseases
12/29
12/29
Donahoe, Michael
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
Collins, Michael T
NCT06474273: TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Not yet recruiting
4
540
Canada, RoW
Methylprednisolone, IV MP, Prednisone
University of Sydney, University of Manitoba
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
12/29
12/29
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT05735015: Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH)

Recruiting
2
30
US
encaleret
National Institute of Dental and Craniofacial Research (NIDCR)
Post-Surgical Hypoparathyroidism
12/25
12/25
VARVARA, NCT05907096: ARGX-117 in Deceased Donor Kidney Transplant Recipients At Risk for Delayed Graft Function

Recruiting
2
102
Europe, Canada, US, RoW
ARGX-117, Placebo
argenx
Delayed Graft Function
04/26
12/26
FUSE-UK, NCT05708963: The U.K. Embryologist Fatigue Study

Completed
N/A
123
US
TMRW Life Sciences, Dudley Associates Healthcare Marketing & Communications
Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain, Back Pain, Neck Pain, Headache, Dizziness, Sleep Disturbance, Chest Pain, Syncope, Cardiovascular Diseases, Shortness of Breath, Gastrointestinal Diseases
01/23
02/23
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
12/23
06/27
T-MD, NCT04549532: Targeted Multidomain () Interventions for Complex Mild Traumatic Brain Injury (mTBI)

Active, not recruiting
N/A
169
US
Targeted Multidomain, Behavioral Management
University of Pittsburgh, Inova Health Care Services, United States Department of Defense
Concussion, Mild
04/25
10/25
VIRTU, NCT06632691: Virtual Reality Headset and Acceptability of Rectosigmoidoscopy in Ulcerative Colitis: a Randomised Controlled Trial

Recruiting
N/A
100
Europe
Virtual reality headset
Centre Hospitalier Departemental Vendee
Haemorrhagic Rectocolitis
04/27
04/27
BHI, NCT04708613: University of Pittsburgh Brain Health Initiative

Recruiting
N/A
300
US
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, Continuous arterial pressure, PET brain imaging, [C-11]6-OH-BTA-1, Pittsburgh Compound B, [F-18]AV-1451, [F-18]T807, LY3191748
David Okonkwo, MD, PhD, National Football League Scientific Advisory Board, Avid Radiopharmaceuticals, Inc., Harvard University
Traumatic Brain Injury
12/25
12/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Kirkwood, John M
NCT00003641: High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Checkmark Data
May 2011 - May 2011: Data
Active, not recruiting
3
1150
Canada, US, RoW
interferon alfa-2b, recombinant interferon alfa, Intron-A, IFN-α 2b, NSC # 377523, observation, clinical observation
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B, NCIC Clinical Trials Group, Children's Oncology Group
Melanoma (Skin)
01/15
10/25
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Withdrawn
1/2
113
US
Tebentafusp (IMCgp100)
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
NCT06599619: Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting
N/A
30
US
Nivolumab, OPDIVO®, Pembrolizumab, Keytruda
John Kirkwood, Melanoma Research Foundation
Melanoma
12/25
12/25
Ramanathan, Ramesh K
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
NCT02925689: Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Active, not recruiting
1
122
US, Canada
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
Mayo Clinic, GlaxoSmithKline, National Cancer Institute (NCI)
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
07/19
 
Anderson, Timothy M
NCT06605807: Optimizing Prescribing Decisions for Hospitalized Older Adults with Chronic Conditions

Not yet recruiting
N/A
150
US
Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.
University of Pittsburgh, National Institute on Aging (NIA)
Prescribing Decisions, Diabetes, Multimorbidity, Hypertension, Geriatrics
03/26
06/26
Argiris, Athanassios
NCT00588770: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
3
403
US, RoW
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
06/18
02/25
NCT01386385: Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Active, not recruiting
1/2
53
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Placebo Administration, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
05/19
12/25
Newman, Anne
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: the Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
NCT00005133: Cardiovascular Health Study (CHS)

Active, not recruiting
N/A
5888
US
National Heart, Lung, and Blood Institute (NHLBI), University of Washington, the Collaborative Health Studies Coordinating Center
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Cerebrovascular Accident, Diabetes Mellitus, Hypertension, Heart Failure, Congestive
10/27
10/27
Jakicic, John
LCBH, NCT03286699: Lifestyle Change for Better Health

Terminated
N/A
8
US
Dietary Intervention, Physical Activity Intervention
University of Pittsburgh, National Cancer Institute (NCI)
Bladder Cancer, Telomere Shortening, Colorectal Adenoma
12/20
10/24
CogEx, NCT03696082: A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines

Terminated
N/A
78
US
Aerobic Activity, Resistance Training, Yoga, Health Education
University of Pittsburgh
Cognition Disorders, Brain Pathology, Physical Disability, Physical Activity, Aging
01/22
12/22
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
NCT06636773: Comparision of Aerobic Exercise to Aerobic Plus Yoga Exercise for Weight Loss in Adults With Overweight or Obesity.

Recruiting
N/A
290
US
Diet, Aerobic Exercise, Behavioral Sessions, Aerobic + Yoga Exercise
University of Kansas Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity and Overweight
11/28
11/28
HEAL, NCT06640179: Evaluation of the Feasibility and Plausible Effectiveness of a Lifestyle Intervention on Change in Weight, Effects on Cardiometabolic Biomarkers, and Kidney Function in Kidney Transplant Recipients

Not yet recruiting
N/A
60
US
Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity
University of Kansas Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplant, Overweight or Obese Adults, Glucose Control
10/26
03/27
M3, NCT06645470: Muscle and Movement With Anti-Obesity Medications

Recruiting
N/A
40
US
Standard Medical Care (SMC), Monitoring Contacts, Aerobic Training, Resistance Training, Nutrition Education
University of Kansas Medical Center, National Institute of General Medical Sciences (NIGMS)
Obesity and Overweight
09/25
12/25
Szabo, Gyongyi
NCT03850899: Alcoholic Hepatitis Network Observational Study

Completed
N/A
1134
US
Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
06/24
06/24
Thase, Michael
SMART-BD, NCT06433635: Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Not yet recruiting
4
2726
Canada, US
Cariprazine, Vraylar, Aripiprazole/Escitalopram combination, Abilify/ Lexapro, Quetiapine, Seroquel, Lurasidone, Latuda
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute
Bipolar I Disorder, Depression
02/30
02/30
NCT04961190: A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

Recruiting
4
300
US
Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR, Pharmacotherapy with Paxil or Effexor XR
University of Pennsylvania, Patient-Centered Outcomes Research Institute, Corporal Michael J. Crescenz VA Medical Center, Coatesville VA Medical Center, Milwaukee VA Medical Center, North Texas Veterans Healthcare System, San Diego Veterans Healthcare System, VA Palo Alto Health Care System, Birmingham VA Health Care System
Posttraumatic Stress Disorder
07/26
07/26
NAP, NCT03668041: National Adaptive Trial for PTSD Related Insomnia

Recruiting
3
774
US
Trazodone, Eszopiclone, Placebo
VA Office of Research and Development
Insomnia
02/26
02/26
NCT00218764: Cognitive Therapy Versus Medication Treatment for Preventing Depression Relapse

Active, not recruiting
N/A
500
US
Fluoxetine (Prozac), Prozac, Cognitive therapy (CT), CT or CBT, Placebo
National Institute of Mental Health (NIMH)
Depression
12/10
12/10
NCT03653637: Group ("Project Life Force") vs. Individual Suicide Safety Planning RCT

Completed
N/A
206
US
Project Life Force, PLF, Treatment as Usual, TAU
VA Office of Research and Development, Corporal Michael J. Crescenz VA Medical Center
Suicide
12/23
03/24
Brent, David A
NCT03825588: Establishing Efficacy of an Inpatient Intervention and Phone App to Reduce Suicidal Risk

Completed
N/A
241
US
ASAP (As Safe As Possible), BRITE smart phone app, TAU (treatment as usual)
University of Texas Southwestern Medical Center, University of Pittsburgh, American Foundation for Suicide Prevention
Suicidal Ideation, Suicide, Attempted
12/22
12/22
Delitto, Anthony
PACBACK, NCT03581123: Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain

Completed
3
1000
US
Supported-Self Management (SSM), Spinal Manipulation Therapy (SMT), SMT + SSM, Standard Medical Care (SMC)
University of Minnesota, University of Pittsburgh, University of Washington, University of North Texas Health Science Center, Oregon Health and Science University, Duke University
Acute Pain, Low Back Pain, Mechanical
06/24
06/24
Lieberman, Frank S
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
HTX-GBM-01, NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
12/25
07/26
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Riddler, Sharon
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT05217641: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

Active, not recruiting
1
108
US
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
HIV Infections
07/23
06/27
NETI, NCT04985760: Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Recruiting
1
32
US
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, HIV-1 Trimer 4571 Vaccine, VRC-HIVRGP096-00-VP, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Phosphate buffered saline, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Madhu Chhanda Choudhary, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
10/25
11/25
DC-HIV04, NCT03758625: Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

Active, not recruiting
1
40
US
a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen
Sharon Riddler, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
03/25
03/25
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Active, not recruiting
1
95
US, RoW
VIR-1388, Placebo
Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network
HIV I Infection
11/25
11/27
McMahon, Deborah
NETI, NCT04985760: Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Recruiting
1
32
US
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, HIV-1 Trimer 4571 Vaccine, VRC-HIVRGP096-00-VP, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Phosphate buffered saline, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Madhu Chhanda Choudhary, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
10/25
11/25
DC-HIV04, NCT03758625: Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

Active, not recruiting
1
40
US
a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen
Sharon Riddler, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
03/25
03/25
NCT05404750: Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Recruiting
N/A
768
US
Harm Reduction
University of Pittsburgh, Allegheny Health Network Research Institute, University of Alabama at Birmingham, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Human Immunodeficiency Virus, Substance Use, Stigma, Social
06/26
06/26
Handen, Benjamin L
DS+ADHD Pilot, NCT04219280: Evaluating Treatment of ADHD in Children with Down Syndrome

Recruiting
4
100
US
Quillivant XR, Placebo
Children's Hospital Medical Center, Cincinnati, University of California, Davis, University of Pittsburgh Medical Center, Boston Children's Hospital, Boston, MA, USA
Down Syndrome, ADHD
09/25
09/25
NCT05916339: AWARE: Management of ADHD in Autism Spectrum Disorder

Recruiting
4
500
Canada, US
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Daniel Coury, Patient-Centered Outcomes Research Institute, University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, University of Rochester Golisano Children's Hospital, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, University of Pittsburgh, Children's Hospital Los Angeles, University of Virginia, University of Alberta, Massachusetts General Hospital, MaineHealth, University of Michigan
ADHD, Autism Spectrum Disorder
01/27
12/27
NCT05418023: Validation of a Salivary miRNA Diagnostic Test for ASD

Recruiting
N/A
6604
US
Salivary Collection, Adaptive Assessment, Medical and Demographic questionnaire, Autism Assessment, Intellectual Development Assessment
Quadrant Biosciences Inc., University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, University of Pittsburgh, University of Massachusetts, Worcester, Children's Hospital Los Angeles, Prisma Health-Upstate, University of Virginia, State University of New York - Upstate Medical University, Rush University, Seattle Children's Hospital, Drexel University, Emory University
Autism Spectrum Disorder, Developmental Delay
07/23
07/23
CST, NCT06038799: Caregiver Skills Training: Comparing Clinician Training Methods

Recruiting
N/A
35
US
Caregiver Skills Training (CST)
University of Pittsburgh, Autism Speaks
Parenting
12/24
12/24
TRC-DS, NCT04165109: Trial-Ready Cohort-Down Syndrome

Recruiting
N/A
450
Europe, US
Flutafuranol, [18F]NAV4694, NAV4694, Pittsburgh Compound (PIB), [11C]-PIB, PIB, MK6240, [18F]MK-6240
University of Southern California, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute
Down Syndrome, Alzheimer Disease, Dementia
12/25
12/25
Greenspan, Susan L
PROUD, NCT02753283: Preventing Osteoporosis Using Denosumab

Completed
4
201
US
denosumab, Prolia, Placebo, Calcium and Vitamin D
Susan L. Greenspan, National Institutes of Health (NIH), National Institute on Aging (NIA)
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
08/23
08/23
NCT05058976: Romosozumab Use to Build Skeletal Integrity

Recruiting
4
200
US
Romosozumab, Evenity, Placebo, Zoledronic acid, Reclast, Calcium and Vitamin D
Susan L. Greenspan, National Institutes of Health (NIH), National Institute on Aging (NIA)
Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
09/27
09/27
Wentzensen, Nicolas
NCT04609072: Connect for Cancer Prevention Study (Connect)

Recruiting
N/A
200000
US
National Cancer Institute (NCI)
Cancer, General Research Use
12/70
12/70
Shneider, Benjamin
NCT02055768: Safety and Efficacy Study of the Intestinal Bile Acid Transport (IBAT) in the Reduction of Pruritus in ALGS

Not yet recruiting
2
24
US, Canada
LUM001 70 ug/kg/day, Intestinal Bile Acid Transport (IBAT) Inhibitor, Placebo, LUM001 140 ug/kg/day
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lumena Pharmaceuticals, Inc.
Pruritus, Alagille Syndrome
02/15
05/15
NCT02922751: FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

Completed
N/A
552
Canada, US
Liver Stiffness Measurement (LSM), FibroScan™
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
12/22
12/22
PROBE, NCT00061828: A Prospective Database of Infants With Cholestasis

Recruiting
N/A
1000
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Biliary Atresia, Neonatal Cholestasis
05/29
05/29
BASIC, NCT00345553: Biliary Atresia Study in Infants and Children

Recruiting
N/A
1265
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Biliary Atresia
05/29
05/29
LOGIC, NCT00571272: Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis

Suspended
N/A
1675
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
05/29
05/29
MITOHEP, NCT01148550: Longitudinal Study of Mitochondrial Hepatopathies

Suspended
N/A
67
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
05/29
05/29
NCT05272319: Genetic Collection Protocol

Recruiting
N/A
2230
Canada, US
Arbor Research Collaborative for Health
Liver Diseases
05/29
05/29
Luketich, James D
NCT01345539: Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Terminated
2
24
US
Stereotactic Radiosurgery (SRS), CyberKnife, Trilogy, True Beam, Chemotherapy
Steven Burton
Oligometastatic Disease
05/22
10/22
NCT03740542: Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy

Active, not recruiting
N/A
140
US
Esophagectomy, Pyloroplasty
University of Pittsburgh
Esophagectomy
02/23
01/25
NCT05591053: Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

Recruiting
N/A
70
US
ActivSight
Activ Surgical, University of Pittsburgh Medical Center, West Penn Allegheny Health System
Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms, Esophageal Diseases, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagus SCC, Esophagus Tumor, Esophagus Adenocarcinoma, Esophagus Neoplasm
01/25
01/25
NCT00280202: Detection of Genetic Markers of Lung Cancer

Recruiting
N/A
6000
US
Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes
University of Pittsburgh, National Institutes of Health (NIH)
Lung Cancer
12/50
12/50
NCT00260572: Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease

Recruiting
N/A
2500
US
Questionnaires to evaluate QOL, Questionnaires to evaluate heartburn and quality of life, Questionnaire to evaluate satisfaction with treatment, Questionnaire to evaluate presence or absence of pain
University of Pittsburgh
Gastroesophageal Reflux Disease
12/50
12/50
NCT00260559: Outcomes After Esophagectomy with a Focus on Minimally Invasive Esophagectomy and Quality of Life

Recruiting
N/A
3500
US
Questionnaires
University of Pittsburgh
Esophagectomy, Esophageal Cancer
12/50
12/50
NCT00260585: Esophageal Cancer Risk Registry

Recruiting
N/A
7000
US
Survey of client health, personal habits, family history, Blood specimen for non-DNA and DNA parts, Biopsy of esophageal/stomach tissue, lymph nodes, tumor, Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies
University of Pittsburgh, National Institutes of Health (NIH), National Cancer Institute (NCI)
Esophageal Cancer, Gastroesophageal Reflux Disease (GERD), Esophageal Diseases, Hiatal Hernia, Esophageal Achalasia
12/50
12/50
Sekikawa, Akira
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Completed
3
1453
US
Placebo, Montelukast
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
07/23
01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
3
10956
US
Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
04/24
04/24
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Completed
3
3214
US
Placebo, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
06/24
11/24
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Active, not recruiting
2
372
US
S-equol, Equelle, Placebo
Akira Sekikawa, National Institute on Aging (NIA)
Arterial Stiffness, White Matter Lesions, Cognitive Decline
10/26
01/27
Palevsky, Paul M
COPE-AKI, NCT05805709: A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the Trial

Recruiting
N/A
2145
US
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury
06/26
03/27
KPMP, NCT04334707: Kidney Precision Medicine Project

Recruiting
N/A
1000
US
Kidney Biopsy, Renal Biopsy, Laparotomy
University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan, Icahn School of Medicine at Mount Sinai, Brigham and Women's Hospital, Broad Institute, The Cleveland Clinic, Columbia University, European Molecular Biology Laboratory, Indiana University, Johns Hopkins University, Joslin Diabetes Center, Pacific Northwest National Laboratory, Princeton University, Stanford University, Ohio State University, University of California, San Diego, University of California, San Francisco, University of Pittsburgh, The University of Texas Health Science Center at San Antonio, University of Texas, Washington University School of Medicine, Yale University
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic
06/27
06/27
Ramalingam, Suresh
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed
1/2
24
US
ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro
Advaxis, Inc.
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
02/22
02/22
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
NCT05493566: Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Emory University, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/25
01/26
Becker, Dorothy
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
NCT00097292: TrialNet Pathway to Prevention of T1D

Recruiting
N/A
75000
Europe, Canada, US, RoW
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 1
07/25
07/25
Caritis, Steve N
NCT03831113: Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

Terminated
2
13
US
Magnitude Group, magnitude, Frequency Group, frequency
Steve N. Caritis, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Opiate Addiction, Pregnancy
12/22
12/22
NCT02863601: Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics

Completed
N/A
25
US
University of Pittsburgh
Opiate Addiction, Pregnancy
05/22
05/22
NCT04183452: 17-OHPC in Pregnancy: IM vs SC Routes

Terminated
N/A
24
US
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-OHPC, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Steve N. Caritis, MD, AMAG Pharmaceuticals, Inc.
Preterm Birth
04/23
04/23
McCann, Sue A
NCT05157581: Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
2
15
US
Extracorporeal photopheresis (ECP), ECP, photopheresis, Methoxsalen Injection, Uvadex
Oleg E. Akilov, MD, PhD, Mallinckrodt
Sezary Syndrome
12/25
12/26
cSCC, NCT05377905: Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer

Recruiting
1/2
48
US
Microneedle Array Doxorubicin (MNA-D), MNA-D, Doxorubicin, Patch
Falo, Louis, MD, National Cancer Institute (NCI)
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
03/25
12/25
MNA-D, NCT02192021: Micro Needle Array-Doxorubicin () in Patients With Cutaneous T-cell Lymphoma (CTCL)

Completed
1
20
US
Micro needle array-Doxorubicin (MNA-D), patch, doxorubicin
Falo, Louis, MD
Cutaneous T Cell Lymphoma
11/20
12/20
 

Download Options